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Abstract
Background: Chromatin adjoining the site of integration of a transgene affects expression and renders
comparisons of closely related transgenes, such as those derived from a BAC deletion series retrofitted with
enhancer-traps, unreliable. Gene targeting to a pre-determined site on the chromosome is likely to alleviate the
problem.
Findings: A general procedure to replace the loxP site located at one end of genomic DNA inserts in BACs with
lox66 is described. Truncating insert DNA from the loxP end with a Tn10 transposon carrying a lox66 site
simultaneously substitutes the loxP with a lox66 sequence. The replacement occurs with high stringency, and the
procedure should be applicable to all BACs in the public domain. Cre recombination of loxP with lox66 or lox71
was found to be as efficient as another loxP site during phage P1 transduction of small plasmids containing those
sites. However the end-deletion of insert DNA in BACs using a lox66 transposon occurred at no more than 20% the
efficiency observed with a loxP transposon. Differences in the ability of Cre protein available at different stages of
the P1 life cycle to recombine identical versus non-identical lox-sites is likely responsible for this discrepancy. A
possible mechanism to explain these findings is discussed.
Conclusions: The loxP/lox66 replacement procedure should allow targeting BACs to a pre-positioned lox71 site in
zebrafish chromosomes; a system where homologous recombination-mediated “knock-in” technology is
unavailable.
Findings
Research Hypothesis
Expression of a transgene integrated into the germline
of an animal is influenced by i) variation in copy num-
ber of transgene and ii) the effect of chromatin adjoin-
ing the site of integration [1]. Thus expression
comparisons of closely related transgenes, such as those
derived from a BAC deletion series retrofitted with
enhancer-traps [2], become unreliable. Targeting trans-
genes to the same site on the chromosome alleviates the
problem, and both “knock-in” technology using homolo-
gous recombination [1] and insertion of cDNA plasmids
into a loxP site have been used in previous studies [3].
Because the lox-Cre recombination reaction/equili-
brium favors excision, mutant sites such as lox66 and
lox71 have been constructed to stably incorporate small
plasmid DNA into chromosomes of plants and mouse
ES cells [4,5]. BACs have not been used similarly, pre-
sumably because altering the loxP or lox511 sites flank-
ing insert DNA in BACs is challenging. We describe a
general procedure that readily overcomes this particular
hurdle of converting a loxP to a lox66 in BACs.
Materials and methods
Two BAC clones from the zebrafish genomic library,
CH211-192O20, & CH211-43O16 designated here as
BACs C & D respectively, were purchased from BAC/PAC
resources, Oakland, California. These zebrafish BACs are
in the pTARBAC2.1 vector. BACs C and D are of size
138.6 and 144.3 kb, respectively, as deduced from the
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BAC contig of this region. They appear closer to 130 kb
on FIGE. End-deletions of insert DNA in BACs were gen-
erated with lox66 transposons using procedures identical
to those described earlier for loxP transposons [6,7].
Briefly, the lox66 transposon plasmid was introduced into
the bacterial host containing the BAC using the calcium
chloride transformation procedure. Transposition into
BAC DNA was initiated by inducing the cells with IPTG.
Cre recombinase was provided by infecting these cells
with phage P1. The resulting end-deleted BACs were
packaged as linear DNA in P1 heads, and used to infect
fresh bacteria to regenerate the lox66 substituted BAC
plasmids. Procedures for DNA isolation/purification from
BAC deletions, FIGE analysis, end-sequencing of BAC
deletions with transposon-based primers have been
described earlier [8,9]. Identical procedures were also fol-
lowed with the BAC deletions generated with lox66
enhancer-trap transposons. Primers used for sequencing
the newly created end of BACs are:
Seq 1......5’ d GACAAGATGTGTATCCACCTTAAC
3’
Seq 4-compliment......5’ d CCGTTTTTAT-
CAGGCTCTGGGAG 3’
LF8-compliment......5’ d CTTGATTCCATT-
CATCTGTAGTG 3’
Results
Cre-recombination of mutant lox sites
Mutant lox sites generated over the years [4,5,10-15] are
of two categories: i) mutations in the 8 bp asymmetric
spacer and ii) mutations in the 13 bp inverted repeats
(Figure 1). The 8 bp spacer region is thought to form
Holiday-like structure with perfect base pairing required
during the recombination process. Single nucleotide dif-
ferences in spacer of two lox sites render recombination
between them very inefficient [10-13,16]. Nevertheless
varying degrees of promiscuity in recombining different
spacer-mutant lox sites have been reported; using both
partially purified Cre-extracts in vitro [10,11,14,15], and
Cre over-expressed in cells [12,13,15,17]. High levels of
stringency in vivo can be achieved however with Cre
protein expressed from its native source namely, a
phage P1 infection [7,16].
Nucleotide substitutions in the 13 bp inverted repeats
(palindromic arms) appear not to severely limit its
recombination with a wild type loxP sequence, and this
tolerance increases for substitutions towards the outer
ends of these inverted repeats [18]. Cre protein binds to
these 13 bp palindromic arms to recombine two lox
sites [18,19], and the protein-protein interactions
between Cre molecules appear to compensate for possi-
ble distortions in Cre binding to mutant-arm DNA.
Wild-type loxP and the arm-mutant lox66 have identi-
cal spacers, and recombine well with Cre [5]. We used
this rationale to substitute a lox66 for the wild-type loxP
site in BACs while truncating the insert DNA using a
lox66 transposon (Figure 1).
Stringency in Cre recombinations between wild type and
mutant lox-sites
While cross recombination between loxP and lox511
had been reported to occur at efficiencies ranging from
5 to 100% in a variety of settings that expressed Cre
constitutively [11-13,15,17], it was determined to be no
more than 0.5% in our BAC end-deletion procedures
where Cre protein is generated by a phage P1 infection
[7,16]. The possibility that phage P1 infection-derived
Cre protein in our procedures might prove too stringent
to allow efficient recombination between loxP and
lox66, despite the fact that lox66 is an arm mutant and
not a spacer mutant like lox511, was explored first by
testing the ability of phage P1, carrying wild type loxP,
to transduce a plasmid containing a lox66 site [16].
Testing Cross Recombination between loxP of phage P1 &
mutant lox sites in plasmids carrying antibiotic resistance
genes with phage P1-derived Cre protein
E. Coli with small plasmids carrying one of several mutant
lox sites and a gene conferring resistance to an antibiotic
were each infected with phage P1. The P1 lysates were
used to infect fresh bacteria, and plated on LB agar con-
taining the antibiotic whose resistance gene was carried by
the plasmid [16]. The results are shown in Table 1.
The results indicate that phage P1 can transduce a
lox66 plasmid just as efficiently as a wild type loxP plas-
mid (compare rows 1 & 2 with 4 in Table 1). However,
phage P1 was unable to transduce plasmids with the
spacer mutants lox511, lox5171 and lox2272 (mutants
described in references 10 and 11), and these were used
as negative controls in the experiment (rows 3, 7 & 8).
The data shown are from two independent experiments.
Note that both the lox “arm mutants”, lox66 and lox71,
are efficiently transduced, while all of the “spacer
mutants”, lox511, lox2272 and lox5171 are not (compare
rows 1, 2, 5, 6 with 3, 7, 8). There was a quantitative
difference between lox511 and lox5171 or lox2272: while
the latter two produced zero colonies on both runs, the
lox511 p r o d u c e d2a n d4c o l o n i e si nt h et w oe x p e r i -
ments. The results are in line with earlier findings
[16,7,5], although the high efficiency of transducing
lox66 and lox71 plasmids by wild type loxP in phage P1
under our more stringent lox-Cre recombination condi-
tions was surprising.
Having demonstrated efficient cross recombination
between lox66 and loxP using phage P1 derived Cre
protein, we tested the lox66 transposons to generate
Chatterjee et al. BMC Research Notes 2010, 3:38
http://www.biomedcentral.com/1756-0500/3/38
Page 2 of 9end-deletions of insert DNA in BACs. The following
lox66 markerless transposon plasmids, similar to our
other markerless transposons reported earlier [20,7],
were constructed (Figure 2).
Progressive end-deletions of insert DNA in BACs with
pTnLox66(B)markerless and pTnLox66(B)markerless
Enhancer-Trap transposons
End deletions of genomic DNA in BAC clone C was
made with pTnLox66(B)markerless transposon (Figure
2, top panel) exactly as described earlier with loxP mar-
kerless transposons [20,7,2]. DNA isolated from a set of
deletions is shown in lanes 3-11, Figure 3A. Note that
inversions of BAC DNA resulting from transpositions of
lox66 in the opposite orientation to that in the BAC
vector (schematic in Figure 3B) are not recovered
because the starting BAC clones are larger than P1-
headful length [20].
End-deletions of insert DNA in a different BAC
clone D with pTnLox66(B)markerless Enhancer-Trap
Figure 1 Schematic diagram for replacing loxP with lox66 in BACs. A set of mutant lox sites is shown in the top panel, with the mutant
nucleotides shown in green. The inverted repeats are underlined. The bottom panel sketches our strategy to convert a wild type loxP to a lox66
mutant site in BACs while making end-deletions of genomic DNA insert from loxP end.
Table 1 Phage P1 transduction of plasmids with mutant
lox sites
Clone Marker Lox Site Transduction with phage P1
a ampR lox66 ++++
b ampR lox66 ++++
c ampR lox511 0
d ampR wt loxP ++++
g ampR lox71 ++++
h ampR lox71 ++++
i camR lox5171 0
j camR lox2272 0
k kanR wt loxP ++++
l kanR wt loxP ++++
0-2 colonies/plate: 0
500-1000 colonies/plate: ++++
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Page 3 of 9transposon (schematic in lower panel of Figure 2) is
displayed in lanes 7-11 of Figure 3, panel A. Not I
sites in pTARBAC2.1 vector DNA in BAC clones is
shown in panel B. Note that the 3827 bp of DNA
between loxP and the Not I site at 2779 is replaced
during recombination of transposed lox66 and loxP in
BAC vector. Thus in deletions with the pTnLox66(B)
markerless transposon the BAC vector band obtained
with Not I digestion is ~6.6 kb (see lanes 3-5 of Figure
3A). Deletions with pTnLox66(B)markerless Enhancer-
Trap transposon results in a Not I vector DNA band
larger by 1.5 kb, (lanes 7-11 Figure 3A), due to the
Not I site being further away in the enhancer-trap (see
lower panel of Figure 2). BAC insert DNA sequencing
with the transposon based primer Seq 1 [9] indicates
D N As i z ei nd e l e t i o n ss h o w ni nl a n e s7 - 1 0a r ea l l
slightly different despite their inadequate resolution in
the FIGE (Figure 3A). This is indicated in the
schematic diagram in panel C of Figure 3, and the
actual sequences included in [Additional File 1].
Progressive end-deletions using the lox66 transposons
were generated at an overall efficiency of 10-20% of that
obtained with the wild type loxP transposons, depending
on whether other recombinogenic sites existed in the
genomic DNA insert of the BAC clone. For example,
efficiency was at the lower end of ~10% with BAC clone
C; which consistently generates a large percentage of
lox-Cre independent internal deletions. As much as
~40% of clones isolated comprise internal deletions of
that particular size shown in lane 6, Figure 3A, when a
wild type loxPmarkerless transposon is used. Note that
lox-Cre independent internal deletions of genomic insert
a r er e a d i l yi s o l a t e dh e r eb e cause there is no selection
for transposition itself in these markerless transposons,
only selection for deleting insert DNA to less than P1
headful packaging capacity (see [20] for discussion).
Figure 2 Schematic representation of the two lox66 transposons constructed. Both use the same framework of markerless transposons
with loxP or lox511 [20,7]. The enhancer-trap is adapted from [2].
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~20% with a different BAC clone D, containing APPb
gene sequences from a different region of the chromo-
some. BAC-D produces far fewer internal deletions (not
shown). The lower efficiency of generating end-deletions
with either of the two lox66 transposons is in sharp con-
trast to the transduction experiments with phage P1,
displayed in Table 1, where no difference was observed
between wild type loxP and lox66 carrying plasmids.
Sequencing newly created end of lox66 BAC deletions in
both directions with transposon based primers
The DNA from BAC deletions generated with the two
lox66 transposons was sequenced with primers comple-
mentary to the transposon end (see [9] for details).
These are seq 1, and seq 4-compliment for deletions
made with pTnLox66(B)markerless transposon, and seq
1 and LF8-compliment for deletions made with
pTnLox66(B)markerless Enhancer-Trap transposon.
While primers Seq 1 and Seq 4 have been described
earlier [9], primer LF8-compliment was designed from
within the intron enhancer of Amyloid Precursor
Protein (APPb) gene [2]. The results are shown schema-
tically in Figure 4.
The Seq 1 primer sits 38 nucleotides from the trans-
poson end, and sequences generated with it read out-
ward into the genomic insert DNA (9). Sequencing BAC
deletions displayed in lanes 3-5 and 7-11 of Figure 3A
with Seq 1 primer indicate that progressive truncations
have occurred from the loxP end of genomic insert
Figure 3 FIGE analysis of BAC DNA isolated from deletions generated with lox66 transposons: Panel A: The BAC DNA was digested with
Not I prior to FIGE. Lane 1 shows DNA from starting BAC-C. Lanes 3-5 and 7-11 display DNA from BAC deletions generated by Cre-
recombination of lox66 with loxP using transposons pTnLox66(B)markerless and pTnLox66(B)markerless Enhancer-Trap transposon, respectively.
Lane 6 shows DNA from a loxP-Cre independent internal deletion. Lane 2 shows a 5 kb ladder. The vector DNA bands generated with Not I a,
b, c, are indicated by the arrows to the left. Size of vector bands b and c are consistent with loxP-Cre dependent recombinations, while vector
band a arises from starting BAC-C or from an internal deletion in BAC-C. DNA from BAC deletions made with pTnLox66(B)markerless transposon
generated the Not I vector band of the expected size (~6.6 kb) shown in lanes 3-5 of Figure 3 (marked by arrow c). The BAC deletion shown in
lane 6 arises from an internal deletion in the genomic insert DNA, and is independent of lox-Cre recombination. The vector DNA band upon Not
I digestion of this clone is 10.6 kb in size, and is identical to that of starting BAC clone C (displayed in lane 1, Figure 3A and marked by arrow a).
This vector DNA band serves as a characteristic identifying feature for internal deletions [20], and can comprise ~90% of isolates in end-deletions
made with certain BAC clones (PKC unpublished observations). These arise due to recombinogenic sites in insert DNA (discussed in [20]). Panel
B: A schematic representation of the Not I sites in pTARBAC2.1 vector DNA in BAC clones is shown. Panel C: Location of ends of lox66
substituted deletion clones in lanes7-10 on zebrafish chromosome 9 is indicated. These were obtained by BLAST analyses of the BAC end
sequences derived with Seq 1 primer [Additional File 1] with the zebrafish genome sequence.
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D respectively. BLAST analyses of these sequences
determine the deletion end points (shown in Figure 3C),
and are consistent with their mobility on FIGE.
Sequences of BAC deletions obtained using either Seq
4-compliment or LF8-compliment read in the opposite
direction, as indicated in Figure 4. The results clearly
demonstrate that the loxP site in the parent BACs have
been replaced with lox66. The sequences in Figure 4
also indicate that restriction enzyme sites in the starting
transposon have been preserved in the BAC deletions
(compare restriction sites in Figures 2 and 4).
Discussion
We describe a general approach to replace the wild type
loxP sequence located at one end of genomic DNA
inserts in all public domain BACs with a lox66 site. The
procedure uses a lox66 transposon to trim insert DNA
from the loxP end and simultaneously replace the origi-
nal loxP with a lox66 site. Replacement of loxP with
lox66 occurs with high fidelity. Although the genomic
DNA insert is truncated in the process, the size of insert
DNA remaining in the lox66 BAC can be as large as 105
kb, the limit encountered by the ~110 kb packaging
capacity of the P1 phage head. The resulting 105 kb
insert DNA size, the remainder being BAC vector, is
unlikely to be a drawback in most applications; because
a majority of vertebrate genes can be housed in their
entirety within this size limit: more than half of non-
coding gene-regulatory sequences in vertebrates are
located within this span of DNA adjoining start sites of
genes [21]. Therefore lox66 BACs housing entire genes
Figure 4 BAC deletions generated with lox66 transposons pTnLox66(B)markerless and pTnLox66(B)markerless Enhancer-Trap
sequenced with Primers Seq 4-compliment and LF8-compliment respectively. Top Panel: Sequence of BAC-C deletions 3, 4, 5, is shown.
The four restriction enzyme sites (4 RE sites) indicated in the schematic representation are Not I, Asc I, Pme I and Pac I, and correspond to sites
in pTnLox66(B)markerless transposon shown in Figure 2 top panel. These sites are highlighted by different colors in the sequence presented.
Bottom Panel: Sequence of BAC-D deletions 7-11 obtained with pTnLox66(B)markerless Enhancer-Trap transposon is shown. The Pac I site is
highlighted in color. Sequence complimentary to the lox66 site is colored and underlined in both panels. Sequencing in the opposite direction
with transposon end-based primer Seq 1 in deletion clones 3-5 and 7-11 indicates zebrafish DNA which BLASTs to chromosome 9 (not shown).
The locations of these sequences on Chr 9 are consistent with end-points of the BAC deletions expected from their sizes on the FIGE gel shown
in Figure 3.
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grated to pre-positioned lox71 sites in chromosomes
using Cre recombination as described earlier for small
plasmids [4,5].
The fidelity of substituting lox66 for loxP in BACs is
high: No truncations occurred from the lox511 side of
genomic DNA insert in our experiments using the lox66
transposons. This should have been easy to detect
because a different sized vector DNA band would have
been generated upon Not I digestion of the DNA (see
Figure 3B). The high fidelity of recombination observed
in the loxP site substitutions is consistent with the
transduction experiments described here (compare rows
1, 2 and 5, 6 with row 3 in Table 1) and with earlier
studies using P1 phage-generated Cre protein [7,16].
The results shown in Figures 3 and 4 indicate that
additional changes, such as incorporating enhancer-
traps [2] or other reporter and/or selectable marker
genes can readily be made in the lox66-BACs during the
substitution process. The methodology should facilitate
targeting functionalized lox66-BACs to a pre-positioned
lox71 site on the chromosome to generate transgenic
animals. The approach should be of special interest in
systems, such as zebrafish, where “knock-in” technology
using homologous recombination are un-available due
to genome duplication in an ancestral teleost [22]. Tar-
geted integration using this strategy has been reported
recently in zebrafish; but only to integrate small lox66
plasmids to lox71 sites on chromosomes [23].
Targeting loxP plasmids to vertebrate genomes can be
affected both by the DNA topoisomerase activity of Cre
protein and cryptic lox sites in chromosomes [24-27].
The topoisomerase activity of Cre is unavoidable, and
might explain the low efficiency of integrating small
lox66 plasmids to chromosomal lox71 sites in zebrafish
[23]. Cryptic lox sites are also likely to reduce efficiency,
although integration at those sites is expected to be less
efficient than at authentic lox71 sites. Despite these
potential complications, targeting of small lox66 plas-
mids to a lox71 site has been successful in zebrafish
[23], plants [4] and mouse ES cells [5,3], and therefore
lox66 BACs should be targetable in a similar manner.
We believe using a lox66 transposon to substitute the
loxP site in BACs should be easier than using homolo-
gous recombination in E.coli because the same lox66
transposon can be used with all BACs in the public
domain. Recombineering approaches on the other hand
require building at least one arm of homology for each
BAC [28-30]. Additional alterations to the BAC are easy
to incorporate with lox66 transposons, but difficult
otherwise.
The overall efficiency of making end-deletions with
the lox66 transposons is 5-10 fold lower compared to
loxP transposons, despite there being no difference
between the two in phage P1 transduction of plasmids
containing either site. This was puzzling. The BAC
end- deletion procedure can be broken down into three
discrete Cre-mediated recombination steps (shown sche-
matically in Figure 5), namely 1) creating the lox66-loxP
deletion in BAC after the lox66 site transposition, 2)
generating the co-integrate between deleted lox66-BAC
and P1 phage, and 3) circularizing the linear BAC DNA
packaged in the phage head upon re-entering fresh bac-
teria (see references 16, 20 for details). Each of these
steps requires Cre recombination between loxP and
lox66 sites. While steps 2) and 3) are common to both
P1 transductions and BAC end-deletion procedures,
step 1) is unique to the latter. Note also that steps 1)
and 3) most likely occur during the early stages of the
P1 infection, with lower levels of Cre protein around,
while step 2) occurs late in infection with probably
higher levels of Cre protein in the cell. It is tempting to
speculate therefore that step 1) is likely to be more
stringent than step 2), and might discriminate between
loxP and lox66 sites so as to slightly disfavor the loxP-
lox66 compared to a loxP-loxP recombination. Thus
fewer truncations are likely to occur with lox66 inserted
into the genomic DNA; resulting in fewer BAC inserts
capable of packaging both the lox66 and loxP sites
within the same phage head that ultimately allows them
to be circularized in the next round of infection [16,20].
Such rationalization would also require that a similar
discrimination in step 3) is not enough to lower survival
of the truncated linear BAC DNA flanked by loxP-lox66
within phage P1 heads through circularization. A delay
in degradation of the linear DNA upon entry into the
cell might be sufficient to overcome this discrimination.
Also other recombinases in the cell might help out in
the process of circularization, as noted earlier [16]. Loss
of stringency of lox-Cre recombinations with higher
levels of Cre protein, proposed for step 2), is most likely
responsible for the wide range of promiscuity observed
in previous studies where Cre was expressed constitu-
tively in cells or used in vitro [11-15,17].
Several interesting conclusions can be drawn from
considering the asymmetry of the lox-Cre recombina-
tion reactions involved in the substitution process.
There is directionality to the loxP site arising from the
8-base asymmetric spacer. Cre-recombination of identi-
cal spacer lox sites occur readily, mutant or otherwise,
while those between non-identical spacers is severely
restricted [16,7]. Thus substitution of the lox511 site at
the other end of insert DNA in BACs with lox66 is
likely feasible when it also carries the same spacer
mutation as lox511. The directionality of the lox-Cre
recombination should also prevent substitution of lox71
for loxP in BACs: because the arm mutation in lox71 is
on the rear end of the arrow shown in Figure 1 (top
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lox71 site into genomic DNA would result in lox71 end-
ing up in the deleted portion of the genomic insert (see
bottom panel of Figure 1). However, transduction of
plasmids carrying lox71 by phage P1 is not affected by
this asymmetry: the lox71 site should end up in seg-
ment F-C of cointegrate rather than segment B-D as in
the case of lox66 (refer to Step 2 of Figure 5). The
linear DNA in the P1 phage head should then be
flanked by loxP at left and lox71 on right, respectively
(Step 3 of Figure 5). Upon Cre-recombination this DNA
should be able to circularize with lox71 in the BAC and
loxP in the small linear piece of DNA from the termini
(step 3 Figure 5).
The lower efficiency of end-deletions with lox66 com-
pared to loxP transposons should not pose a hurdle
because several thousand deletion clones are generated
in each deletion/substitution experiment, and one can
screen a sufficient number of clones to obtain the
desired number of lox66 substituted BAC deletions.
Using this end-deletion/substitution procedure, BACs as
large as 110 kb with loxP replaced by lox66 can be gen-
erated with minimal effort using the same lox66 trans-
poson for all BACs in the public domain.
Additional file 1: Sequences of BAC deletion ends. Sequences of the
end points of the BAC deletions shown in lanes 7-10, Figure 3, on
zebrafish chromosome 9. These were obtained by direct BAC end-
sequencing with the Seq 1 primer located in the transposon end
retained in the deletion clone.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-0500-3-38-
S1.DOCX]
Abbreviations
BAC: bacterial artificial chromosome; FIGE: Field inversion gel electrophoresis;
APPb: Amyloid Precursor Protein.
Figure 5 A schematic representation of the three Cre-recombination steps in the end-deletion/lox66 substitution process. Step 1 shows
the end-deletion of genomic insert DNA by the transposed lox66 site recombining with the loxP endogenous to the BAC clone. Step 2 illustrates
co-integrate formation between lox66 APPb BAC and P1 phage DNA carrying loxP. Step 3 shows regeneration of circular lox66 BAC from the
linear DNA in the phage head after infection of fresh bacteria. The lox511 site at the other end of genomic insert DNA is omitted for clarity
purposes, as it does not play any role in Cre recombinations with either lox66 or loxP. Note that the relative position of the two lox sites in the
linear DNA inside the phage head determines whether lox66 or loxP is retained in the BAC. This in turn is determined by the location of the
“pac site” in the co-integrate shown in Step 2 (see [16,20], for detailed discussion).
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